BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to makepre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting with developing countries.

Website LinkTwitter LinkLinkedin Link
Founder
David Tsao
Founded
2017
Invested in
2017
DeepTech
Why we invested

Billion to one sees an opportunity in molecular diagnostics, a quickly growing sector attributed to the increasing adoption of point-of-care and rapid testing. The U.S. in vitro diagnostics market worth $55.29 billion in 2021 with molecular diagnostics account the largest share of 49.03%. Led by Dr. Oguzhan Atay, Billion to one aims to unlock improvements to non-invasive prenatal screening and liquid biopsy.

Wei Guo
Wei Guo
Founding Partner
View more unicorns